SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) may represent an important component of cardiac toxicity after thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). However, the available evidence remains limited and heterogeneous.
methodsWe conducted a systematic review and meta-analysis of observational studies evaluating AF after thoracic radiotherapy in NSCLC. PubMed, Scopus, Web of Science, Embase, and Cochrane Central were searched from inception to March 2026. The primary outcome was pooled new-onset AF. A separate exploratory analysis evaluated cumulative incidence of AF at reported follow-up intervals using random-effects models.
resultsNine retrospective cohort studies were included in the systematic review, and eight were eligible for quantitative synthesis. Six of the eight studies contributed to the primary analysis, whereas two did not report the primary outcome in a directly comparable format, including 4410 patients and 736 events. The pooled proportion of new-onset AF was 0.14 (95%CI 0.07-0.24), with substantial heterogeneity (I2 = 94.0%). Three studies contributed to the cumulative-incidence analysis, although the pooled estimate was highly imprecise (0.09, 95% CI, 0.00-0.84; I2 = 0.0%). Across studies, AF risk appeared to be associated with radiation exposure to cardiac substructures, particularly the sinoatrial node, pulmonary veins, and atrial structures.
conclusionAF may represent a clinically relevant component of cardiac toxicity after thoracic radiotherapy in NSCLC, but the current evidence remains limited by retrospective study design and marked heterogeneity, underscoring the need for prospective validation and standardized outcome reporting.
Indexed as
Identifiers
42251230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.